WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative healthcare company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today reported preliminary

To be Available in March 2016 WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it received a 510(k) clearance (K152954) from the U.S. Food and Drug Administration (FDA) for an upgraded version of Quell, the company's over-the-counter, 100% drug free chronic

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the Biotech Showcase 2016 Conference being held in San Francisco, CA. Dr. Gozani intends to provide an overall business update and a

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin , Senior Vice President and General Manager, Consumer will participate in a panel titled "Wearables: Sleeker Smarter Faster" on Thursday, January 7 at 4:30pm (Pacific) at the 2016 CES Event in Las

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants. The Company sold to a healthcare dedicated institutional investor 13,800 shares of Series C convertible preferred stock at a

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NASDAQ : NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 13,800 shares of Series C convertible preferred stock at

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today reported the commercial launch of DPNCheck in Mexico . The initial DPNCheck order will be utilized by one of Mexico's six major government healthcare institutions to improve the detection of diabetic neuropathy and advance the

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced that Shai N. Gozani , M.D., Ph.D., President and CEO, will participate in a panel titled "Roadmap to FDA Approval" on Tuesday, January 5 at the 2016 CES Event in Las Vegas . The panel moderator is Alfred Poor , Editor of

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell is available for purchase at FSAstore.com and HSAstore.com , the only e-commerce sites stocked exclusively with eligible products for Flexible Spending Account (FSA) and Health Savings Account (HSA)

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell has been selected as one of 10 finalists in the Last Gadget Standing event at CES 2016. Now in its 15th year, Last Gadget Standing is one of the best loved and longest running events at the International